P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Greg J. Riely; Rina Hui; David P. Carbone; K. Park; Marion Carrigan; X. Xu; T. Dang; James Chih‐Hsin Yang

doi:10.1016/j.jtho.2018.08.637

P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Greg J. Riely(Memorial Sloan Kettering Cancer Center), Rina Hui(The University of Sydney), David P. Carbone(The Ohio State University), K. Park(Samsung Medical Center), Marion Carrigan(Merck & Co., Inc., Rahway, NJ, USA (United States)), X. Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), T. Dang(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Chih‐Hsin Yang(National Taiwan University Hospital)

Journal of Thoracic Oncology

October 1, 2018

10.1016/j.jtho.2018.08.637

Cited by 23

Abstract

Related Papers

No related papers found

Powered by citation graph analysis